|
Match
|
Document |
Document Title |
|
|
US20090053213 |
Anti-Gm-Csf Antibodies and Uses Therefor
The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or...
|
|
|
US20080292619 |
Pharmaceutical Composition Containing Meltrin Antagonist
Mainly concerning the pharmaceutical field, it is intended to exert an inhibitory effect on the function of meltrin α of promoting the differentiation of adipocytes by preparing a compound serving...
|
|
|
US20080181885 |
NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 202P5A5 USEFUL IN TREATMENT AND DETECTION OF CANCER
A novel gene 202P5A5 and its encoded protein, and variants thereof, are described wherein 202P5A5 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the...
|
|
|
US20080124324 |
Single-domain antigen-binding antibody fragments derived from llama antibodies
A phage display library of variable heavy domain (V H H or VH) fragments (sdAb fragments) derived from the antibody repertoire of a non-immunized llama is disclosed. The sdAb fragments of the...
|
|
|
US20080118508 |
Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an...
|
|
|
US20080112955 |
METHOD AND COMPOSITION FOR PREVENTING PAIN IN SICKLE CELL PATIENTS
A method of preventing pain in a sickle cell patient is disclosed. The method includes orally administering to the patient, an amount of an active agent effective on oral administration to inhibit...
|
|
|
US20080112954 |
Method for treating chronic pain
The present invention provides a method for treating a chronic pain by administering to an individual in need of such treatment with a pharmaceutically effective amount of a blocking reagent for...
|
|
|
US20080112953 |
Stable formulations
The invention provides a formulation including an acetic acid buffer, a glutamic acid buffer or a succinic acid buffer with a pH from about 4.5-7.0, at least one excipient comprising a sugar or a...
|
|
|
US20080112950 |
Naturally occurring IgM antibodies that bind lymphocytes
Human and animal serum contains naturally occurring autoantibodies that develop at birth in absence of deliberate immunization. These antibodies are predominantly of IgM isotype but can include all...
|
|
|
US20080107651 |
Humanized Neutralizing Antibodies Against Hemolytic Uremic Syndrome
Novel human monoclonal antibodies derived from a transgenic mouse are disclosed as well as a process for the preparation of the novel monoclonals and a therapeutic method of treating an individual...
|
|
|
US20080107650 |
METHOD FOR TREATING INFLAMMATORY DISEASES OF THE DIGESTIVE TRACT
A method for treating an inflammatory disease of the digestive tract, for example inflammatory bowel disease, in a subject comprises administering to the subject a therapeutically effective amount...
|
|
|
US20080107649 |
Immunogenic compositions of cyclic peptides derived from the beta-amyloid peptide
The present invention relates to biologically active compositions and methods forelliciting an immune response, particularly against amyloid beta peptides by combinatory use of virosomes as...
|
|
|
US20080102069 |
TUMOR THERAPY WITH A COMBINATION OF ANTI-HER2 ANTIBODIES
The present invention provides a method for treating HER 2 positive cancer or metastasis of HER 2 positive cancer in a patient, who does not respond to a monotherapy with trastuzumab or a...
|
|
|
US20080095774 |
Agents and Methods for Specifically Blocking CD28-Mediated Signaling
The instant invention provides compositions and methods for downmodulation of immune responses, e.g., autoimmune responses. For example, methods of downmodulating an immune response using agents...
|
|
|
US20080095773 |
POLYPEPTIDES HOMOLOGOUS TO VEGF AND BMP1
The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor...
|
|
|
US20080095772 |
ANTIBODIES AGAINST HUMAN PARATHYROID HORMONE RELATED PROTEIN
Disclosed are an antibody against human para-thyroid-hormone-related protein, a DNA coding for the antibody, a recombinant vector containing the DNA, a transformant transformed with the recombinant...
|
|
|
US20080095771 |
Treatment Method
The invention provides methods of treating autoimmune diseases using lower doses of anti-CD20 antibodies effective to deplete B cells in the patient.
|
|
|
US20080095770 |
Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or...
|
|
|
US20080095769 |
IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS
The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and...
|
|
|
US20080095768 |
USE OF ALLOGENEIC EFFECTOR CELLS AND ANTI-CS1 ANTIBODIES FOR SELECTIVE KILLING OF MULTIPLE MYELOMA CELLS
Methods for treating MM using anti-CS1 antibodies are provided herein.
|
|
|
US20080095767 |
ENGINEERED ANTIBODIES WITH NEW WORLD PRIMATE FRAMEWORK REGIONS
The present invention provides an antibody or antigen-binding portion thereof having a variable region comprising at least two complementarity determining regions (CDRs) and at least three...
|
|
|
US20080095766 |
Methods for the Treatment of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies with Reduced Toxicity
The present invention provides methods of treating, preventing, slowing the progression of, or ameliorating the symptoms of T cell mediated immunological diseases, particularly autoimmune diseases...
|
|
|
US20080095700 |
DR4 antibodies and uses thereof
Death Receptor 4 (DR4) antibodies are provided. The DR4 antibodies may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treatment and diagnosis using the DR4...
|
|
|
US20080089931 |
EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders
The present invention relates to methods and compositions designed for treatment, management, or prevention of a hyperproliferative cell disease, particular cancer. The methods of the invention...
|
|
|
US20080089923 |
Biodegradable ocular implants and methods for treating ocular conditions
Biodegradable ocular implants are described. The ocular implants include a bioactive agent that can be released within the eye to treat an ocular condition or indication. The implants can be used...
|
|
|
US20080089887 |
Members of the FC Receptor Homolog Gene Family (FcRH1-3,6) Related Reagents and Uses Thereof
The invention relates to members of the Fc receptor homolog (FcRH) subfamily, as well as fragments and variants thereof. Each FcRH is a Type I transmembrane receptor, preferably, comprises an...
|
|
|
US20080089838 |
Chimeric, Human and Humanized Anti-CSAP Monoclonal Antibodies
The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers,...
|
|
|
US20080085277 |
NOVEL ANTIGEN-BINDING POLYPEPTIDES AND THEIR USES
Novel antigen-binding polypeptides (ABP) and uses thereof are provided.
|
|
|
US20080085275 |
METHODS OF MODULATING APOPTOSIS BY ADMINISTRATION OF RELAXIN AGONISTS OR ANTAGONISTS
The present invention relates to the discovery that relaxin is associated with the development or maturation of body tissues. Knockouts of the gene encoding relaxin result in various abnormalities...
|
|
|
US20080081038 |
NOVEL ANTIGEN-BINDING POLYPEPTIDES AND THEIR USES
Novel antigen-binding polypeptides (ABP) and uses thereof are provided.
|
|
|
US20080075721 |
METHOD OF TREATING FIBROSIS
Materials and methods for treating fibrosis in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf3...
|
|
|
US20080075719 |
Method for Augmenting B Cell Depletion
The present invention provides methods of augmenting B cell depletion by promoting intravascular access of B cell subsets sequestered in lymphoid tissues rendering the B cells sensitive to killing...
|
|
|
US20080075718 |
Films and Particles
Described herein are compounds and processes that can be used to prepare polymer-based films, particles, gels and related compositions, and processes for delivery of agents, and other uses.
|
|
|
US20080075659 |
Proteins with high immunoreactivity and method for their production
The invention relates to (glyco-) proteins, in particular monoclonal antibodies, which have an immunoreactivity of >81%, preferably >90%. The inventive monoclonal antibodies are produced...
|
|
|
US20080069817 |
HETEROARYL-FUSED PYRIMIDINYL COMPOUNDS AS ANTICANCER AGENTS
Heteroaryl-fused pyrimidinyl compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the...
|
|
|
US20080069816 |
HUMANIZED ANTI-CEA T84.66 ANTIBODY AND USES THEREOF
Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84.66 antibody. The technique used to generate these antibodies utilizes...
|
|
|
US20080069815 |
ANTI-OSTEOPONTIN ANTIBODY AND USE THEREOF
An anti-osteopontin antibody which inhibits the binding of an integrin recognizing RGD sequence to osteopontin or its fragment, and which inhibits the binding of an integrin recognizing SVVYGLR...
|
|
|
US20080069814 |
Prevention of Thrombotic Disorders with Active Vitamin D Compounds or Mimics Thereof
The present invention relates to a method for preventing, treating, or ameliorating thrombotic disorders in an animal comprising administering to the animal an active vitamin D compound or a mimic...
|
|
|
US20080069772 |
Treatment of transformed or infected biological cells
The present invention relates to a therapeutic or/and diagnostic substance. Furthermore it relates to an expression vector, to a composition comprising the afore-mentioned substance or/and the...
|
|
|
US20080063639 |
Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
The present invention relates to a method for the prevention or for the treatment of psoriasis comprising administering to a patient in need thereof an effective amount of an isolated antibody, or...
|
|
|
US20080063598 |
Humanized Antibody
Novel humanized and chimeric antibodies, humanized antibody fragments, polypeptides sequences of such antibodies and derivatives thereof that specifically bind AF-20 are provided as well as methods...
|
|
|
US20080057060 |
METHOD AND SYSTEM TO REMOVE CYTOKINE INHIBITOR IN PATIENTS
A method to treat cancer uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's...
|
|
|
US20080057059 |
Pharmaceutical Composition Comprising Factor VII Polypeptides and Protein S Inhibitors
The present invention relates to a composition comprising factor VII or a factor VII-related polypeptide and a protein S inhibitor, and the use thereof for treating bleeding episodes.
|
|
|
US20080057058 |
USES OF IL-23 AGONISTS AND ANTAGONISTS; RELATED REAGENTS
Provided are methods of treatment for tumors. In particular, methods are provided for modulating activity of a cytokine molecule and its receptor.
|
|
|
US20080050375 |
BINDING COMPOSITIONS: RELATED REAGENTS
TGF-beta 1 binding compositions and reagents related thereto are provided. Methods of using such compositions for thereaputic purpose are also provided.
|
|
|
US20080050374 |
NOVEL ANTIGEN-BINDING POLYPEPTIDES AND THEIR USES
Novel antigen-binding polypeptides (ABP) and uses thereof are provided.
|
|
|
US20080050373 |
TREATMENT WITH ANTI-ERBB2 ANTIBODIES
The present invention concerns the treatment of cancer with anti-ErbB2 antibodies.
|
|
|
US20080050372 |
INHIBITION OF ALPHA-2 HS GLYCOPROTEIN (AHSG/FETUIN) IN OBESITY AND INSULIN CONTROL OF GLUCOSE HOMEOSTASIS
α2-Heremans Schmid Glycoprotein (AHSG) inhibits insulin-induced autophosphorylation of the insulin receptor (IR) and IR-tyroskine kinase (TK) activity; genetic ablation of the Ahsg gene enhances...
|
|
|
US20080050371 |
CD16A Binding Proteins and Use for the Treatment of Immune Disorders
CD16A binding proteins useful for the reduction of a deleterious immune response asre described. In one aspect, humanized anti-cd16A antibodies, optionally lacking effector function, are used for...
|
|
|
US20080050370 |
Stabilized polypeptide compositions
The invention is based, at least in part, on the development of stabilized binding molecules that consist of or comprise a stabilized scFv and methods for making such stabilized molecules.
|